Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

NLRP4 negatively regulates type I interferon response and influences the outcome in anti-programmed cell death protein (PD)-1/PD-ligand 1 therapy.

Cancer science - 1 Mar 2022

Wang Hui, Xia Liliang, Yao Cheng-Cheng, Dong Hui, Yang Yi, Li Chong, Ji Wen-Xiang, Sun Rui-Ming, Duan Huang-Qi, Mengzhou Wenli, Xia Wei-Min, Wang Shu-Jun, Ji Ping, Li Ziming, Jiao Lei, Wang Ying, Lu Shun

Abstract excerpt

The challenge to improve the clinical efficacy and enlarge the population that benefits from immune checkpoint inhibitors (ICIs) for non-small-cell lung cancer (NSCLC) is significant. Based on whole-exosome sequencing analysis of biopsies from NSCLC patients before anti-programmed cell death protein-2 (PD-1) treatment, we identified NLRP4 mutations in the responders with a longer progression-free survival (PFS)....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to B7-H1 Antigen
Share to CD8-Positive T-Lymphocytes

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immune Checkpoint Inhibitors

Share to Interferon Type I

Share to Lymphocytes, Tumor-Infiltrating

Share to Programmed Cell Death 1 Receptor

Share to Progression-Free Survival

Share to Tumor Microenvironment

Source

Open in PubMed Open full text

Identifiers

PMID: 34927309
DOI: 10.1111/cas.15243
PMCID: PMC8898729

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

NLRP4 negatively regulates type I interferon response and influences the outcome in anti-programmed cell death protein (PD)-1/PD-ligand 1 therapy.PMID 34927309Read ↗

ARID1A deficiency reverses the response to anti-PD(L)1 therapy in EGFR-mutant lung adenocarcinoma by enhancing autophagy-inhibited type I interferon production.Semantic proximity Read ↗

PD-L1 Expression in NSCLC: Clouds in a Bright SkySemantic proximity Read ↗

Human NLRC4 expression promotes cancer survival and associates with type I interferon signaling and immune infiltrationSemantic proximity Read ↗

Targeting NTRK1 Enhances Immune Checkpoint Inhibitor Efficacy in NTRK1 Wild-Type Non-Small Cell Lung Cancer.Semantic proximity Read ↗

A scoping review on the significance of programmed death-ligand 1-inhibiting microRNAs in non-small cell lung treatment: A single-cell RNA sequencing-based studySemantic proximity Read ↗

PD-L1 lncRNA splice isoform promotes lung adenocarcinoma progression via enhancing c-Myc activitySemantic proximity Read ↗

Molecular profiling of long‐term responders to immune checkpoint inhibitors in advanced non‐small cell lung cancerSemantic proximity Read ↗

Lung adenocarcinoma–derived IFN-γ promotes growth by modulating CD8+ T cell production of CCR5 chemokinesSemantic proximity Read ↗

DUSP11 is an intracellular innate immune checkpoint in lung adenocarcinomaSemantic proximity Read ↗

AGO2 mediates immunotherapy failure via suppressing tumor IFN-gamma response-dependent CD8+ T cell immunitySemantic proximity Read ↗

MER4 endogenous retrovirus correlated with better efficacy of anti-PD1/PD-L1 therapy in non-small cell lung cancerSemantic proximity Read ↗

Toll-like receptor4 and 8 are overexpressed in lung biopsies of human non-small cell lung carcinomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.